Leveraging the power of HTS in the new and rapidly evolving collaborative drug discovery landscape
Posted: 1 December 2018 | Dr David C. Murray (Hit Discovery - Discovery Sciences - IMED Biotech Unit - AstraZeneca), Dr Mark D. Wigglesworth (Hit Discovery - Discovery Sciences - IMED Biotech Unit - AstraZeneca) | No comments yet
Over the last five years drug discovery has undergone a rapid evolution from a closed and proprietary endeavour to an open and collaborative process. Large and small pharma now openly collaborate with each other and the wider academic world to leverage their collective depth of knowledge to increase the chances of discovering new medicines that improve patients’ lives.
Related topics
Drug Discovery, High Throughput Screening (HTS), Mass Spectrometry